MQR not paying geologist, page-12

First 12 Last

Share
Profile

Follow
Simusangg

85 Posts.

6

04/01/24

13:39

Post #: 71724839
Share

Originally posted by giddyup007: ↑

I already know what happened and advised you of that fact. I am not a shareholder of MQR but BEA.
When BEA optioned the Kenieba and Lone Star properties (great properties by the way) to MQR, BEA took 6 million MQR shares priced at $0.15 (or $900,000) as part of the deal. Today those shares are worth $150,000 and the 2 properties now have questionable value.
As a BEA shareholder that really pisses me off. I'm not pissed at BEA management as my BEA shares held their value through all this but I'm pissed at MQR. And to top it all off MQR had the audacity to sue BEA for some bullshit story about BEA not giving MQR 80% of Kenieba. What a bunch of cry babies!
When MQR completed the drilling and they earned the rights to 80%, BEA told MQR right away "Hey MQR congratulations, now create a new JV company with 80% of the shares owned by MQR and 20% owned by BEA, and when that is done BEA will transfer the Kenieba property into the new JV company and MQR will own 80% of Kenieba"
So if MQR really really wanted the property that's all they had to do. But after the questionable drill results they were in no hurry, and in fact to delay the transfer of the property even further they decided to sue BEA. And sue for what? BEA refuses to transfer the property. When in fact it should be BEA suing MQR for failing to take the property and take over 80% of future expenditures.
And yes MQR did file papers in the British Columbia law courts to initiate the law suit but haven't proceeded any further. Maybe when they got the first bill from the very expensive B.C. lawyers they used, they realized that they were on a potentially very expensive path to which they could not win.

So in the end I say to you, no it shouldn't be me that phones Chuck but you as a MQR shareholder should be making that call and get some answers for yourself. After all it's your money.

Expand

great information, thanks for this. Im surprised noone has decided to correct you, especially this is quite serious. Ive had doubts on the board for a long time, it is only good to take a punt everytime it reaches low 2c and wait for them to use the old MIN news again.

MQR Price at posting: 2.7¢ Sentiment: None Disclosure: Not Held
8 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 52 more messages in this thread...

First 12 Last

Add MQR (ASX) to my watchlist

(20min delay)
Last 1.6¢		Change 0.000(0.00%)		Mkt cap ! $6.662M

Open	High	Low	Value	Volume
1.7¢	1.7¢	1.6¢	$6.02K	370.0K

Buyers (Bids)

No.	Vol.	Price($)
1	42402	1.6¢

Sellers (Offers)

Price($)	Vol.	No.
1.7¢	500000	2

View Market Depth

No.	Vol.	Price($)
1	42402	0.016
5	746300	0.015
3	465991	0.014
2	83846	0.013
4	288666	0.012

Price($)	Vol.	No.
0.017	500000	2
0.019	90333	2
0.020	1114500	7
0.021	721414	3
0.022	521741	4

Last trade - 14.16pm 07/10/2024 (20 minute delay)

MQR (ASX) Chart

MQR not paying geologist, page-12

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MQR not paying geologist, page-12

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News